Could Down syndrome be eliminated? Scientists say cutting-edge gene editing tool could cut out extra chromosome
Cutting-edge gene editing technology could eradicate Down syndrome, according to Japanese scientists.
Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in the United States, is caused by the presence of an extra copy of chromosome 21.
The extra chromosome, also known as trisomy 21, causes cellular overactivity, compromises a range of processes within the body, and can manifest in distinctive physical traits, learning difficulties, and health concerns.
Advertisement
Now new research out of Mie University in Japan suggests that by using the DNA-modifying tech CRISPR, it is possible to remove the surplus chromosome in affected cells and bring cellular behavior closer to typical function.
3 Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in the United States, is caused by the presence of an extra copy of chromosome 21.
Mongkolchon – stock.adobe.com
CRISPR-Cas9 is a gene-editing system that utilizes an enzyme to identify specific DNA sequences. Once the enzyme locates a matching site, it snips through the DNA strands.
Ryotaro Hashizume and his colleagues designed CRISPR guides to target only the trisomy 21 chromosome, a process called allele-specific editing, which directs the cutting enzyme to the desired spot.
Advertisement
When they used it on lab-grown cells, removing the extra copy of the gene normalized the way the genes expressed themselves in the body — suggesting that the genetic burden had been removed.
They also found that after the extra chromosome was removed, genes tied to nervous system development were more active and those related to metabolism were less active. This backs up previous research that found extra copies of chromosome 21 disrupt brain development during early fetal growth.
Researchers also tested their CRISPR guides on skin fibroblasts, which are mature, non-stem cells taken from people with Down syndrome.
Advertisement
In these fully developed cells, the editing method successfully removed the extra chromosome in a number of cases.
3 Hashizume and his team designed CRISPR guides to target only the trisomy 21 chromosome, a process called allele-specific editing, which directs the cutting enzyme to the desired spot.
Gorodenkoff – stock.adobe.com
After removal, these corrected cells grew faster and had a shorter doubling time than untreated cells, suggesting that removing the extra chromosome may help with the biological strain that slows down cell growth.
Advertisement
But the CRISPR can affect healthy chromosomes, too, and researchers are refining their program so that it only attaches to the extra copy of chromosome 21.
This work proves that, rather than making small fixes, CRISPR can eliminate an entire chromosome.
The scientists published their findings in PNAS Nexus.
Hashizume and his team are hopeful that their work may be used to design regenerative therapies and treatments that address genetic surplus at its source.
3 Researchers also tested their CRISPR guides on skin fibroblasts, mature, non-stem cells taken from people with Down syndrome.
Yakobchuk Olena – stock.adobe.com
Researchers will continue to analyze the risks of DNA changes and monitor how modified cells function over time and their viability in real-world settings.
A recent case study explored a medical mystery related to Down syndrome; the brain of an American woman with Down syndrome showed all the classic signs of Alzheimer's disease, yet she remained symptom-free throughout her lifetime.
Advertisement
People with Down syndrome face a much higher risk of developing Alzheimer's-related dementia as they age — an estimated three to five times higher than the general population.
Scientists are still working to pinpoint the exact cause, but it's believed that the extra copy of chromosome 21 drives the overproduction of amyloid precursor protein. This excess production leads to the buildup of amyloid beta plaques in the brain, a hallmark of Alzheimer's disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
6 hours ago
- New York Post
Fossilized ‘Dragon Man' skull clears up baffling ‘mystery' behind early humans: scientists
A skull, unearthed nearly a century ago, has led to new revelations in the study of human evolution. Known as 'Dragon Man,' the fossil has now been identified as belonging to the Denisovans — a mysterious group of ancient humans whose existence was first revealed through DNA analysis in 2010. The 'Dragon Man' belongs to the Denisovans — a mysterious group of ancient humans. Hebei GEO University Advertisement 'I really feel that we have cleared up some of the mystery surrounding this population,' Qiaomei Fu, a researcher who was a part of the 2010 discovery team and led the new study, told CNN. 'After 15 years, we know the first Denisovan skull.' The findings also provide a glimpse into what the Denisovans may have looked like. Scientists have reconstructed an artist's impression of 'Dragon Man,' showing a robust, blocky face with strong brow ridges, a feature common in other ancient human species. Advertisement With a brain size comparable to both Neanderthals and modern humans, Denisovans would have had a physically powerful appearance, likely adapted to the harsh environments they inhabited. The 'Dragon Man' skull, which dates to 146,000 years ago and was discovered in 1933 by a laborer in Harbin City, China — when it was under Japanese occupation — was long shrouded in mystery. The worker had found the cranium while building a bridge, but rather than handing it over to science, he stashed it at the bottom of a well, where it remained untouched for decades until his death in 2018. His family then donated it to Hebei GEO University, CNN reported. The 'Dragon' Man skull, which was discovered in 1933 by a laborer in Harbin City, China, was long shrouded in mystery. Vertebrate Paleontology and Paleoanthropology of the Chinese Academy of Sciences Advertisement With the discovery of this nearly complete skull, scientists have finally pieced together a face for the Denisovans, offering new insights into the history of humanity. In 2021, scientists first proposed that the skull might belong to a new species of human, naming it Homo longi, or 'Dragon Man,' which is derived from Heilongjiang, or Black Dragon River, the province where the it was found. The skull's unusual features — such as its massive brow ridges and broad, low face—were unlike those of any previously known human species. However, as exciting as this discovery was, it raised many questions. Advertisement The mystery deepened as researchers struggled to extract DNA from the skull, which had been buried for so long. Despite several attempts, initial efforts to analyze its genetic material proved unsuccessful. It wasn't until scientists turned to a different source — dental plaque — that they found the breakthrough they needed. The DNA pointed to a surprising connection to the Denisovans, an ancient human group that had been identified through a tiny pinky bone found in a Siberian cave over a decade ago. The discovery of this fossil marked the first evidence of Denisovans outside of their original home in Siberia. Until now, no complete Denisovan skull had ever been found, leaving researchers with only small pieces of the puzzle to work with. The 'Dragon Man' skull changes that, providing a much-needed clue to help scientists piece together what these ancient relatives might have looked like. The new research, published in two groundbreaking papers in Cell and Science, not only provided mitochondrial DNA evidence but also revealed protein fragments extracted from the skull that further cemented its Denisovan identity. The analysis of these proteins showed a clear match to known Denisovan traits, confirming the connection beyond doubt. The 'Dragon Man' discovery adds a new layer to our understanding of human evolution, shedding light on a period when multiple human species roamed the Earth. Denisovans, Neanderthals, and early Homo sapiens coexisted and even interbred, leaving behind traces of their DNA in modern humans. In fact, many people today carry small amounts of Denisovan DNA, a legacy of these ancient encounters.
New York Post
14 hours ago
- New York Post
Could Down syndrome be eliminated? Scientists say cutting-edge gene editing tool could cut out extra chromosome
Cutting-edge gene editing technology could eradicate Down syndrome, according to Japanese scientists. Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in the United States, is caused by the presence of an extra copy of chromosome 21. The extra chromosome, also known as trisomy 21, causes cellular overactivity, compromises a range of processes within the body, and can manifest in distinctive physical traits, learning difficulties, and health concerns. Advertisement Now new research out of Mie University in Japan suggests that by using the DNA-modifying tech CRISPR, it is possible to remove the surplus chromosome in affected cells and bring cellular behavior closer to typical function. 3 Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in the United States, is caused by the presence of an extra copy of chromosome 21. Mongkolchon – CRISPR-Cas9 is a gene-editing system that utilizes an enzyme to identify specific DNA sequences. Once the enzyme locates a matching site, it snips through the DNA strands. Ryotaro Hashizume and his colleagues designed CRISPR guides to target only the trisomy 21 chromosome, a process called allele-specific editing, which directs the cutting enzyme to the desired spot. Advertisement When they used it on lab-grown cells, removing the extra copy of the gene normalized the way the genes expressed themselves in the body — suggesting that the genetic burden had been removed. They also found that after the extra chromosome was removed, genes tied to nervous system development were more active and those related to metabolism were less active. This backs up previous research that found extra copies of chromosome 21 disrupt brain development during early fetal growth. Researchers also tested their CRISPR guides on skin fibroblasts, which are mature, non-stem cells taken from people with Down syndrome. Advertisement In these fully developed cells, the editing method successfully removed the extra chromosome in a number of cases. 3 Hashizume and his team designed CRISPR guides to target only the trisomy 21 chromosome, a process called allele-specific editing, which directs the cutting enzyme to the desired spot. Gorodenkoff – After removal, these corrected cells grew faster and had a shorter doubling time than untreated cells, suggesting that removing the extra chromosome may help with the biological strain that slows down cell growth. Advertisement But the CRISPR can affect healthy chromosomes, too, and researchers are refining their program so that it only attaches to the extra copy of chromosome 21. This work proves that, rather than making small fixes, CRISPR can eliminate an entire chromosome. The scientists published their findings in PNAS Nexus. Hashizume and his team are hopeful that their work may be used to design regenerative therapies and treatments that address genetic surplus at its source. 3 Researchers also tested their CRISPR guides on skin fibroblasts, mature, non-stem cells taken from people with Down syndrome. Yakobchuk Olena – Researchers will continue to analyze the risks of DNA changes and monitor how modified cells function over time and their viability in real-world settings. A recent case study explored a medical mystery related to Down syndrome; the brain of an American woman with Down syndrome showed all the classic signs of Alzheimer's disease, yet she remained symptom-free throughout her lifetime. Advertisement People with Down syndrome face a much higher risk of developing Alzheimer's-related dementia as they age — an estimated three to five times higher than the general population. Scientists are still working to pinpoint the exact cause, but it's believed that the extra copy of chromosome 21 drives the overproduction of amyloid precursor protein. This excess production leads to the buildup of amyloid beta plaques in the brain, a hallmark of Alzheimer's disease.
Newsweek
20 hours ago
- Newsweek
CEO Says New Tool Allows Couples To 'Genetically Optimize Their Children'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The CEO of a U.S.-based biotech company that developed software to enable parents to select embryos used for in vitro fertilization (IVF) based on genetic markers, told Newsweek that this "genetic optimization" would help people "live longer and thrive." Kian Sadeghi created his DNA testing and analysis company Nucleus to "give parents direct insights into whatever matters most to them when they choose their embryo." Nucleus offers the world's first genetic optimization software that allows parents to have preferences over their child's genetics during the IVF process, with the aim of reducing preventable genetic disease. "There's no moment when parents need to know how genetics will impact them and their loved ones more than when they're preparing to start a family," Sadeghi said. Genetic disease impacts millions of children in the U.S., with Down syndrome, Thalassemia, cystic fibrosis, Tay-Sachs disease and sickle cell disease among the most common. As well as screening for these sorts of conditions, Nucleus also analyses embryos for chronic conditions like Alzheimer's disease and heart disease. In total, it checks for almost 1,000 traits and conditions, from cystic fibrosis to heart disease, cancer risks, and mental health conditions like anxiety and ADHD. Kian Sadeghi, CEO of biotech company Nucleus, told Newsweek that "genetic optimization" would help people "live longer and thrive." Kian Sadeghi, CEO of biotech company Nucleus, told Newsweek that "genetic optimization" would help people "live longer and thrive." Newsweek/Getty Images/Canva Sadeghi said that many families "have experienced death at the hands of these common conditions and seek to prevent similar suffering." He told Newsweek that his own experience of the loss and grief brought on by genetic disease was actually what guided him to set up his company. When he was 7 years old, his 15 year-old cousin suddenly died in her sleep from what he said was a "preventable genetic disease." "My parents were heartbroken and terrified that my siblings and I would have the same fate," he said. Being so young at the time, Sadeghi said "it didn't make sense to me why someone would drop dead at 15, when other 15-year-olds are fine." He said that the loss of his cousin was the the first time he "intuitively grasped this idea of generational health." "Seeing this genetic lottery, when someone wins and someone doesn't, really stuck with me," he said. As he grew up, he developed a keen interest in genetics in school and by the time he got to college he was determined to create software that "could prevent what happened to my family from happening to anyone else in the world." After dropping out of the University of Pennsylvania, he then set up Nucleus in 2020, and believes that his software will spare families from the grief he himself felt when he lost a loved one to a preventable genetic disease. Kian Sadeghi, CEO of Nucleus, a company that has developed software to help parents screen their embryos for genetic conditions. Kian Sadeghi, CEO of Nucleus, a company that has developed software to help parents screen their embryos for genetic conditions. Uncredited/Nucleus Sadeghi added that his company is "democratizing access to genetic information," as at the moment, he said genetic testing results can be hard to decipher without a clear explanation from a doctor. "We're putting comprehensive, actionable data directly in parents' hands with tools that let them actually understand and compare their options," Sadeghi said. However, given that the software allows parents to genetically "optimize" their children, it raises various ethical questions, ones which members of the public have taken to social media to ask. Some social media users on X, formerly known as Twitter, voiced their concern that genetic screening could have unknown, secondary impacts, while others criticized Nucleus for oversimplifying the issue, saying "we can't predict longevity even for adults, so how can we possibly do this for embryos." Discussing ethical issues raised by the public, Sadeghi said, "until now, how this science would impact how we have children and how we would deploy it has been discussed only behind closed doors—not in public." He said now that Nucleus has announced the availability of the technology, the public has the opportunity to "listen to each other, hear each other out, and use this information to establish their views to ensure the insight Nucleus Embryo can provide is put to good use." Sadeghi added that the best way to have the public understand the technology was "to have them use it," and that it was important to make it accessible to as many people as possible. There have also been concerns raised about whether genetically optimizing IQ in embryos could increase risk of mental health conditions like schizophrenia. Sadeghi said that his company's report on schizophrenia risk for embryos noted that the condition is linked to both bipolar disorder, as well as intelligence, and that ADHD, OCD, Alzheimer's disease and autism were also linked to intelligence. He added that "we always educate parents on links between high disposition to neurological diseases and exceptional traits." "When you analyze genes for disease risk, you're also uncovering insights into traits, since both share a common genetic foundation," he said. The software, while being offered to parents to help them prevent their children from developing genetic disease, therefore does come with ethical considerations—considerations which will continue to be explored and discussed in public, now that the technology has brought the issue into the spotlight.
